{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:20:38Z","timestamp":1773026438015,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.pupt.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T20:17:01Z","timestamp":1536697021000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study"],"prefix":"10.1016","volume":"53","author":[{"given":"Corrado","family":"Pelaia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Busceti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2018.09.006_bib1","doi-asserted-by":"crossref","first-page":"15025","DOI":"10.1038\/nrdp.2015.25","volume":"1","author":"Holgate","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.pupt.2018.09.006_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","volume":"391","author":"Papi","year":"2018","journal-title":"Asthma, Lancet"},{"key":"10.1016\/j.pupt.2018.09.006_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2018.09.006_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib5","doi-asserted-by":"crossref","first-page":"879783","DOI":"10.1155\/2015\/879783","article-title":"Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma","author":"Pelaia","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.pupt.2018.09.006_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and non-eosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/ajrccm.164.8.2010002","article-title":"Interleukin-5 induces CD34+ eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma","volume":"164","author":"Stirling","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrd3838","article-title":"Targeting eosinophils in allergy, inflammation and beyond","volume":"12","author":"Fulkerson","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pupt.2018.09.006_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major sub-phenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(00)00690-7","article-title":"Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone","volume":"406","author":"Zhang","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pupt.2018.09.006_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01167-2017","article-title":"Asthma and corticosteroids: time for a more precise approach to treatment","volume":"49","author":"Dunican","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.09.006_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nrd3792","article-title":"The potential of biologics for the treatment of asthma","volume":"11","author":"Pelaia","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pupt.2018.09.006_bib13","first-page":"104315","article-title":"Update on anticytokine treatment for asthma","author":"Gallelli","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pupt.2018.09.006_bib14","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.chest.2017.05.019","article-title":"New anti-eosinophil drugs for asthma and COPD: targeting the trait","volume":"152","author":"Bel","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2018.09.006_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40259-017-0215-8","article-title":"Interleukin-5 inhibitors for severe asthma: rationale and future outlook","volume":"31","author":"Shrimanker","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.pupt.2018.09.006_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14712598.2018.1492540","article-title":"Biological therapies for eosinophilic asthma","volume":"18","author":"Patel","year":"2018","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.pupt.2018.09.006_bib17","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","article-title":"Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.pupt.2018.09.006_bib18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2147\/TCRM.S111862","article-title":"Role of biologics in severe eosinophilic asthma: focus on reslizumab","volume":"12","author":"Pelaia","year":"2016","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.pupt.2018.09.006_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17425255.2018.1421170","article-title":"Pharmacokinetic\/pharmacodynamic profile of reslizumab in asthma","volume":"14","author":"Matera","year":"2018","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.pupt.2018.09.006_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1358\/dot.2017.53.12.2736670","article-title":"Benralizumab for the treatment of asthma","volume":"53","author":"Matera","year":"2017","journal-title":"Drugs Today"},{"key":"10.1016\/j.pupt.2018.09.006_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/DDDT.S155307","article-title":"Benralizumab in the treatment of severe asthma: design, development and potential place in therapy","volume":"12","author":"Pelaia","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.pupt.2018.09.006_bib22","first-page":"4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","author":"Pelaia","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.pupt.2018.09.006_bib23","first-page":"321","article-title":"Technology evaluation: mepolizumab, GlaxoSmithKline","volume":"5","author":"Gnanakumaran","year":"2003","journal-title":"Curr. Opin. Mol. Therapeut."},{"key":"10.1016\/j.pupt.2018.09.006_bib24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/ACI.0000000000000183","article-title":"Mepolizumab-based therapy in asthma: an update","volume":"15","author":"Walsh","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.09.006_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/imt.15.102","article-title":"Mepolizumab in the treatment of severe eosinophilic asthma","volume":"8","author":"Fainardi","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.pupt.2018.09.006_bib26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2018.09.006_bib27","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma \u2013 clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib30","article-title":"Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma","author":"Kurosawa","year":"2018","journal-title":"J Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.09.006_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaci.2012.08.023","article-title":"The asthma control test and the asthma control questionnaire for assessing asthma control: systematic review and meta-analysis","volume":"131","author":"Jia","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.09.006_bib32","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2018.09.006_bib33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib34","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.09.006_bib35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib37","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12325-018-0727-8","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"35","author":"Ortega","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pupt.2018.09.006_bib38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2018.09.006_bib39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2018.09.006_bib40","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jaip.2017.11.026","article-title":"Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma","volume":"6","author":"Gunsoy","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.pupt.2018.09.006_bib41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1183\/09031936.00165106","article-title":"Severe exacerbations predict excess lung function decline in asthma","volume":"30","author":"Bai","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.09.006_bib42","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Therapeut."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918302128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918302128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T02:17:50Z","timestamp":1751854670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553918302128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":42,"alternative-id":["S1094553918302128"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2018.09.006","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}